DFTX Stock Surges 53% on Successful Phase 3 Trials for LSD-Based Depression Drug
Key Facts
In a move reflecting growing optimism for next-generation mental health therapies, Definium announced positive topline results from its Phase 3 Emerge study evaluating DT120. According to reports, the company's shares, traded on NASDAQ under the ticker DFTX, recorded a massive 53% increase during Monday's session. The clinical trial for major depressive disorder, which utilizes an orally disintegrating formulation of lysergide (LSD), met its primary and all key secondary efficacy endpoints.
This achievement highlights the intensifying competition in the innovative psychiatric treatment landscape, where firms like Sage Therapeutics and Axsome Therapeutics are racing to capture market share. Per market data, the 53% surge positions DFTX as a top performer in the biotech sector today, as successful Phase 3 outcomes typically precede Biologics License Application (BLA) filings with the FDA.
Technically, traders are monitoring the price momentum for DFTX following its significant breakout at the close of June 22, 2026. Looking at the economic calendar, the market awaits US consumer sentiment data in the coming days, which will be a key catalyst for risk appetite regarding growth stocks and small-cap healthcare entities.
Latest Updates · 2
- Notable·
Update: Detailed clinical data revealed that DT120 achieved an 8.1-point improvement over placebo, significantly exceeding analyst expectations. The treatment demonstrated rapid efficacy within one week that was sustained for 12 weeks, driving DFTX shares to a peak of $37.90 during Monday's session.
- Major·
Update: Definium Therapeutics capitalized on its clinical momentum by announcing a $500 million public offering to fund its business operations. In broader sector news, AbbVie has agreed to acquire Apogee Therapeutics for $135.11 per share in cash, signaling a surge in M&A activity within the biotechnology landscape.